Since 2011, when the anti-CTLA-4 Ipilimumab first obtained FDA approval for the treatment of metastatic melanoma [34,35], the number of ICIs has rapidly expanded to include indications in different tumor types and disease settings (Table 1) (www.fda.gov, accessed on 15 November 2022). The gene discussed is CTLA4; the disease is neoplasm.